What you need to know about biotech’s biggest event of the year

The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and expensive hotel rooms.

January 4, 2024 Check out STAT+

Sponsored By

Alex Hogan/STAT STAT+ | Burning questions for the 2024 JPM Healthcare Conference The J.P. Morgan conference, which begins Monday in San Francisco, will be a barometer of whether newfound optimism in biotech will persist in 2024. By Damian Garde and Adam Feuerstein and Allison DeAngelis and Matthew Herper and Mohana Ravindranath STAT+ | Another major pharma company departs BIO UCB left the biotech industry group BIO at the end of 2023, the second major member company to exit after Pfizer pulled out. By Rachel Cohrs Opinion: Insurance companies are forcing psychiatrists like me to stop accepting their coverage Insurance companies like to say they cover psychiatrists. But then they make it impossible for us to do our jobs. By Andrew Popper André Chung for STAT Baby monitor videos yield evidence for long-suspected link between seizures and unexplained toddler deaths Researchers report that videos provide evidence of a long-suspected link between seizures and toddler deaths. By Eric Boodman STAT+ | Feng Zhang's year-old CRISPR delivery startup Aera lays off quarter of staff The layoffs come amid a biotech market downturn. Aera is one of several startups trying to solve a key bottleneck in genetic medicine. By Jason Mast STAT+ | An injectable gel enters the male birth control fray with early positive clinical data An injectable, reversible hydrogel made by Contraline could fill the male birth control void between condoms and vasectomies. By Lizzy Lawrence Paul A. Volberding STAT+ | Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer Company is ending late-stage lymphoma trials and will test therapy on earlier cancers, a concession to competition from personalized CAR-T. By Adam Feuerstein STAT+ | Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs The deals, which are valued at as much as $1.06 billion, are focused on developing treatments for obesity and MASH. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser